Treatment with Verona Pharma’s investigative drug RPL554 can effectively improve lung function in patients with chronic obstructive…
Articles by Alice Melão, MSc
A mutation of the PDGFD gene is linked to an increased risk of adrenal gland suppression, a serious side effect of…
A new subset of stem cells was found to expand quickly after lung injury and to specifically restore the tissues…
Better and more adequate home-based care for patients with chronic obstructive pulmonary disease (COPD) can significantly improve their quality…
Long-term use of Tudorza (aclidinium bromide) can significantly and safely reduce exacerbations in people with moderate to severe…
Verona Pharma has enrolled more than half of the 400 COPD patients it is seeking for a Phase 2b clinical trial…
Pooled data from three Phase 3 clinical trials shows that the investigative SUN-101/eFlow product is well-tolerated and improves lung…
Verona Pharma’s lead investigational medicine RPL554, engineered to treat patients with chronic obstructive pulmonary disease (COPD) and other…
The U.S. Food and Drug Administration has approved a triple combination treatment developed by GlaxoSmithKline as a maintenance therapy for chronic obstructive…
A new computer model based on anatomical and experimental information can predict changes in lung function caused by chronic inflammation.